00:07:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-11-03 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-10 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-09-06 Extra Bolagsstämma 2022
2022-08-04 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning OPTOMED 0.00 EUR
2022-05-10 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning OPTOMED 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning OPTOMED 0.00 EUR
2020-06-11 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Optomed är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.
2022-10-27 14:00:00

Optomed PlcInside Information27 October 2022 at 15.00, Helsinki

Inside information, profit warning: Optomed decreases its full year outlook

Optomed decreases its full year 2022 outlook due to uncertainty in China. The Company now expects its full year 2022 revenue to stay on the same level as in 2021. While globally Optomed's sales channels have performed well, uncertainty in the Chinese markets continues, affecting on Optomed's short term revenue prospects. 

The updated outlook for 2022:

"Optomed expects its full year 2022 revenue to stay on the same level as in 2021."

Previously outlook (announced 17 February 2022):

"Optomed expects its full year 2022 revenue to grow compared to 2021."

Optomed utilizes three thresholds in relation to its revenue guidance: in Optomed's outlook, the revenue may "grow/decrease significantly", "grow/decrease" or "stay on the same level". The Company has set fixed internal percentages to reflect each threshold.
Optomed will publish the Interim Report for January-September 2022 on 3 November 2022.
Optomed Plc

Further enquiries

Seppo Kopsala, CEO, seppo.kopsala@optomed.com

Sakari Knuutti, CFO, sakari.knuutti@optomed.com 

Optomed in Brief

Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company's products are sold via various sales channels in over 60 countries globally

www.optomed.com